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Abstract
Background
Published estimates of mortality and progression to AIDS as children with HIV approach
adulthood are limited. We describe rates and risk factors for death and AIDS-defining events
in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17
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middle- and high-income countries, including some in Western and Central Europe
(W&CE), Eastern Europe (Russia and Ukraine), and Thailand.
Methods and findings
Children with perinatal HIV aged <18 years initiating cART were followed until their 21st
birthday, transfer to adult care, death, loss to follow-up, or last visit up until 31 December
2013. Rates of death and first AIDS-defining events were calculated. Baseline and time-
updated risk factors for early/late (/>6 months of cART) death and progression to AIDS
were assessed. Of 3,526 children included, 32% were from the United Kingdom or Ireland,
30% from elsewhere in W&CE, 18% from Russia or Ukraine, and 20% from Thailand. At
cART initiation, median age was 5.2 (IQR 1.4–9.3) years; 35% of children aged <5 years
had a CD4 lymphocyte percentage <15% in 1997–2003, which fell to 15% of children in
2011 onwards (p < 0.001). Similarly, 53% and 18% of children5 years had a CD4 count
<200 cells/mm3 in 1997–2003 and in 2011 onwards, respectively (p < 0.001). Median follow-
up was 5.6 (2.9–8.7) years. Of 94 deaths and 237 first AIDS-defining events, 43 (46%) and
100 (42%) were within 6 months of initiating cART, respectively. Multivariable predictors of
early death were: being in the first year of life; residence in Russia, Ukraine, or Thailand;
AIDS at cART start; initiating cART on a nonnucleoside reverse transcriptase inhibitor
(NNRTI)-based regimen; severe immune suppression; and low BMI-for-age z-score. Cur-
rent severe immune suppression, low current BMI-for-age z-score, and current viral load
>400 c/mL predicted late death. Predictors of early and late progression to AIDS were simi-
lar. Study limitations include incomplete recording of US Centers for Disease Control (CDC)
disease stage B events and serious adverse events in some countries; events that were dis-
tributed over a long time period, and that we lacked power to analyse trends in patterns and
causes of death over time.
Conclusions
In our study, 3,526 children and adolescents with perinatal HIV infection initiated antiretrovi-
ral therapy (ART) in countries in Europe and Thailand. We observed that over 40% of deaths
occurred6 months after cART initiation. Greater early mortality risk in infants, as com-
pared to older children, and in Russia, Ukraine, or Thailand as compared to W&CE, raises
concern. Current severe immune suppression, being underweight, and unsuppressed viral
load were associated with a higher risk of death at >6 months after initiation of cART.
Author summary
Why was this study done?
• Adolescence has been highlighted as an urgent global priority for health by a diverse
range of stakeholders.
• HIV/AIDS is one of the top 10 leading causes of death in adolescents globally.
• Estimates of mortality and progression to AIDS as children approach adulthood are
limited.
Mortality/AIDS in children on ART in Europe/Thailand
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What did the research do and find?
• We investigated long-term risk of death and AIDS-defining events in children and ado-
lescents with perinatal HIV across high- and middle-income country settings in West-
ern and Central Europe, Eastern Europe (Russia, Ukraine), and Thailand.
• In our study, in 3,526 patients across 17 countries, median age at cART initiation was
5.2 years, and median duration of follow-up was 5.6 years, with 9,228 person-years of
follow-up in those aged10 years and 20,574 person-years overall.
• We found that there was a higher risk of mortality in very young children, in Eastern
European countries and Thailand, and in patients with current severe immune suppres-
sion and low BMI.
What do these findings mean?
• We describe outcomes for some of the first generation of children to survive perinatal
HIV and reach adolescence.
• Our findings, together with other available evidence, suggest an ongoing need for inten-
sive monitoring of very young children with HIV infection, those with severe immuno-
suppression, and those with a lower BMI than that expected for their age.
Introduction
Studies have reported declining mortality since the introduction of combination antiretroviral
therapy (cART) about 20 years ago, both in adults and children [1–3]. For example, in the
United Kingdom (UK) and Irish nationwide paediatric cohort, among 1,441 children with
median age 9 years at last follow-up, mortality rates declined from 8.2 per 100 person-years
before 1996 to 0.6 in 2003–2006 [1]. In an Italian multicentre study, survival of children with
perinatal HIV significantly improved between 1996 and 1998, following the introduction of
cART [4]. Similarly, in a United States cohort of 3,553 children with median age at enrolment
of 6 years and median follow-up of 5 years, mortality rates declined from 7.2 to 0.8 per 100 per-
son-years between 1994 and 2000 and remained relatively stable to the end of 2006 [2]. Mortal-
ity rates in adults have shown a similar trend, and life expectancy among those with a CD4
count500 cells/mm3 is now thought to be close to that of the general population [5].
However, AIDS is now a top 10 leading cause of death in adolescents globally [6], and evi-
dence suggests worsening outcomes as children with HIV grow up and transition to adult
care. European data from individual cohorts suggest that young people with perinatal HIV
infection have a higher risk of treatment failure [7–10], care disengagement [11], and death
[12] compared to those who acquire HIV in adulthood and children with other routes of trans-
mission. Thus, there is the need for vigilance to ensure that health outcomes in this population
who have survived paediatric HIV are maximised as they enter adulthood.
Longitudinal cohort studies are well placed to measure changes in mortality rates over time.
However, due to relatively limited numbers of children with perinatal HIV infection in some
European countries [13], pooling of data across cohorts is the only practical way of obtaining
reliable mortality rates across the European region. The European Pregnancy and Paediatric
Mortality/AIDS in children on ART in Europe/Thailand
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HIV Cohort Collaboration (EPPICC) is a network of 19 cohorts across 17 countries in Western
and Central Europe (W&CE), Eastern Europe (Russia, Ukraine), and Asia (Thailand). In this
study, data from these cohorts were used to describe rates and risk factors for mortality and
AIDS-defining events in perinatally HIV-infected children and adolescents after initiating cART.
Methods
This study was carried out in accordance with the EPPICC Paediatric merger 2014 SOP and
the project-specific Concept Sheet (S1 Text). Nineteen cohorts across 17 countries contributed
to individual patient data (see S2 Text: “Writing Group members and collaborating cohorts”
for list of collaborators). Children were included in this analysis if they had perinatal HIV
infection and initiated cART (defined as a3 drug,2 class regimen [excluding unboosted
PIs] or3 non-nucleoside reverse transcriptase inhibitor [NNRTI]-only regimen, including
abacavir) after 1996 (with no prior antiretroviral therapy [ART] use), aged <18 years. They
were at risk from cART initiation until their censor date, defined as the earliest of 21st birth-
day, last visit in paediatric care, death, or loss to follow-up (as defined by each cohort), with
data available until 31 December 2013. Demographic, clinical, laboratory, and treatment-
related data from routine clinic visits (typically every 3–6 months) were pooled electronically
using a modified HICDEP protocol (www.hicdep.org). Pooled data were subjected to a battery
of consistency checks. Data on all children at participating clinics were included; data are
pseudo-anonymised, and therefore individual informed consent was not obtained. All cohorts
received approval from local and/or national ethical committees. For example, the UK/Ireland
CHIPS cohort had approval from the London Central Research Ethics Committee.
Causes of death, along with CD4 and clinical event data, were reviewed by the Project
Team and confirmed by the reporting clinician. Cause of death was coded using the Interna-
tional Classification of Diseases version 10 and categorised into 4 groups: HIV-related infec-
tious causes, other HIV-related causes, deaths not directly related to HIV, and those with
unknown cause. AIDS events were considered to be reliably reported, as they are an important
clinical indicator of disease progression for children in routine care.
Statistical methods
Rates of death and first AIDS-defining event were calculated per 100,000 person-years. Rates
were summarised overall, within 6 months of ART initiation (‘early’; children were at risk
from ART initiation to ART initiation plus 6 months), and after 6 months of ART (‘late’; at
risk from ART initiation plus 6 months to their censor date), and rates of first AIDS-defining
event were additionally summarised by event. Early deaths and AIDS-defining events were
summarised separately, as they were likely to be related to late presentation/initiation of cART.
AIDS-defining events were classified according to the US Centers for Disease Control and Pre-
vention 2014 surveillance criteria [14]. Cohorts reported date of AIDS diagnosis as the date of
the child’s earliest WHO stage 3/4 or US Centers for Disease Control (CDC) stage C event.
Continuous variables were compared using Wilcoxon’s rank-sum test and categorical variables
using a chi-squared test.
Risk factors for early death, late death, early first AIDS-defining event, and late first AIDS-
defining event were assessed using univariable and multivariable proportional hazard models
with inverse-probability-of-censoring weights. The probability of being censored was esti-
mated using logistic regression (including all factors listed below) to account for informative
censoring in those lost to follow-up. Weights were calculated as the reciprocal of these esti-
mated probabilities. Association with the following factors at cART initiation were considered:
age (continuous), sex, ethnicity (black African, Asian, other, unknown), year of birth
Mortality/AIDS in children on ART in Europe/Thailand
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(continuous), born abroad (versus in country of cohort), country group (Eastern Europe and
Thailand [EE&T] [Russia/Ukraine/Thailand]) versus W&CE (all others), previous AIDS diag-
nosis (yes, no), year of cART initiation (continuous), initial regimen (NNRTI-based, other),
World Health Organization (WHO) severe immune suppression for age (defined as a CD4
lymphocyte percentage [CD4%] <25% for children <1 year of age, <20% for children aged
1–3 years, <15% for children aged 3–5 years, and<200 cells/mm3 or<15% for children aged
5 years [15]), viral load (100,000 c/mL, >100,000 c/mL), and BMI-for-age z-score (>0,
0–−3,<−3, calculated using WHO child growth standards, 2007).
Time-updated factors considered for late death and first AIDS event were age, severe
immune suppression for age, HIV viral load, BMI-for-age z-score, and proportion of time sup-
pressed since cART initiation (80% versus<80%, as a proxy for adequate adherence). Values
for time-updated factors based on clinical/laboratory measurements were considered to occur
on the date recorded and were carried forward for up to 6 months (if no subsequent measure-
ment was recorded), after which they were considered to be unknown. Individuals with miss-
ing data for any given factor were classified as missing, with a separate level of the variable (the
missing indicator method).
Nonlinear effects of continuous variables were explored using natural cubic splines with 5
knots, and in final models, where appropriate, statistically significant nonlinearity was repre-
sented by piecewise linear functions. All characteristics (excluding those that were highly cor-
related) were included in a multivariable model. Covariate interactions between country
group, calendar year of ART initiation, and any other statistically significant (p< 0.05) charac-
teristics were considered and the proportional hazards assumption assessed.
BMI-for-age z-score was chosen rather than weight-for-age z-score, as WHO has normative
data across all ages for BMI for age (WHO reference data for weight are only available for chil-
dren aged<10 years), and to minimise differences due to variation in height for age between
ethnic groups in the general population. A sensitivity analysis used weight-for-age z-score
based on UK normative data for Western, Central, and Eastern European cohorts and Thai
normative data for the Thai cohort. Analyses investigating rates and risk factors for early and
late AIDS events separately were not prespecified but conducted following discussion of the
results from a combined analysis investigating overall rates of AIDS events. Statistical analyses
were performed using Stata version 14.2 (Stata Corporation, College Station, Texas). STROBE
recommendations were followed (S1 STROBE Checklist).
Results
Of 3,953 HIV-infected, ART-naïve children in EPPICC at the time of initiating cART, 3,526
(89%) acquired HIV perinatally and were eligible for this analysis; 1,124 (32%) were from the
UK or Ireland, 700 (20%) from Thailand, 508 (14%) from Ukraine, and 1,194 (34%) from else-
where across Europe (Table 1). The median age at cART initiation for the 3,526 participants
was 5.2 (IQR 1.4–9.3) years, and the median year of cART initiation was 2006 (2003–2009).
Median duration of follow-up was 5.6 (2.9–8.7) years, with 20,574 person-years of follow-up
overall (of which 4,531 were of participants aged <5 years, 6,836 aged 5–<10 years, 6,577 aged
10–<15 years, 2,139 aged 15–<18 years, and 512 aged18 years).
At cART initiation, 1,491/2,719 (55%) children overall had severe immune suppression
for their age (466/555 [84%] for Thailand) and 663 (19%) had a previous AIDS diagnosis. The
proportion of children aged<5 years at ART initiation who had a CD4% less than 15%
declined over the study period, from 35% (134/381) in 1997–2003 to 15% (24/157) from 2011
onwards (p< 0.001) (Fig 1), and similarly, the proportion aged5 years with a CD4 count
<200 cells/mm3 at cART initiation declined from 53% (194/365) to 18% (36/196) (p< 0.001).
Mortality/AIDS in children on ART in Europe/Thailand
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Table 1. Characteristics of children overall, and by timing of death, for those who died.
Characteristics Overall
(N = 3,526)
Died6 months after cART initiation
(N = 43)
Died >6 months after cART initiation
(N = 51)
n (%) or median [IQR]
Sociodemographics:
Country of cohort Belgium 71 (2) 0 1 (2)
France 124 (4) 0 1 (2)
Germany 17 (0.5) 0 0
Greece 20 (1) 0 0
Italy 206 (6) 1 (2) 1 (2)
the
Netherlands
160 (5) 0 0
Poland 51 (1) 1 (2) 0
Portugal 28 (1) 0 0
Romania 28 (1) 0 0
Russia 132 (4) 1 (2) 2 (3)
Spain 258 (7) 0 1 (2)
Sweden 64 (2) 0 0
Switzerland 35 (1) 0 1 (2)
Thailand 700 (20) 25 (58) 29 (57)
UK/Ireland 1,124 (32) 12 (28) 13 (25)
Ukraine 508 (14) 3 (7) 2 (4)
Sex Male 1,670 (47) 18 (42) 21 (41)
Female 1,856 (53) 25 (58) 30 (59)
Ethnic group Black African 1,176 (33) 10 (23) 13 (25)
Asian 723 (21) 25 (58) 29 (57)
Other† 982 (28) 6 (14) 5 (10)
Unknown 645 (18) 2 (5) 4 (8)
Born abroad 1,081 (32) 8 (23) 9 (20)
Year of birth <2000 1,632 (46) 25 (58) 39 (76)
2000 1,894 (54) 18 (42) 12 (24)
Characteristics at HIV diagnosis:
Age (years) 2.7 [0.7–7.4] 5.6 [0.5–8.0] 7.9 [2.2–10.3]
CD4% (n = 1,580, 23, 20) 19 [10–29] 11 [1–22] 5 [1–16]
Characteristics at cART initiation:
Age (years) 5.2 [1.4–9.3] 6.2 [0.6–9.9] 8.1 [4.6–10.8]
Age5 years 1,804 (51) 26 (60) 35 (69)
AIDS diagnosis 663 (19) 26 (60) 14 (27)
Calendar year 1997–2003 973 (28) 19 (44) 30 (59)
2004–2007 1,264 (36) 13 (30) 16 (31)
2008 1,289 (37) 11 (26) 5 (10)
Initial cART regimen NNRTI-based 2,227 (63) 36 (84) 43 (84)
PI-based 1,140 (32) 7 (16) 6 (12)
Other 159 (4) 0 2 (4)
CD4% (n = 2,677, 41, 34) 16 [9–25] 5 [1–14] 5 [1–15]
CD4 count (age5 years) (n = 1,436, 25, 22) 242 [85–410] 14 [7–29] 55 [10–134]
Immune suppression for age (n = 2,719,
42, 35)
Not severe 1,228 (45) 6 (14) 5 (14)
Severe 1,491 (55) 36 (86) 30 (86)
Viral load (log10 c/mL) (n = 2,481, 33, 30) 5.0 [4.4–5.7] 5.5 [4.9–5.9] 5.3 [4.3–5.7]
Height-for-age z-score (n = 1,877, 30, 27) −1.2 [−2.3–−0.2] −3.4 [−4.4–−2.1] −2.3 [−3.4–−1.8]
(Continued)
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By the end of the study period, 94 (3%) children had died, 453 (13%) had been lost to fol-
low-up, 305 (9%) had transferred to adult care, 314 (9%) had dropped out for other reasons
(including having moved to another clinic or withdrawn consent), and 2,322 (66%) were still
in follow-up. Among those still in paediatric care, the median age at last visit was 11.6 (7.6–
15.0) years.
Causes of death
There were 94 deaths, of which 43 (46%) were within 6 months of cART initiation. Among the
early deaths, 37% (16/43) occurred within 1 month and 79% (34/43) within 3 months of cART
start. The crude mortality rate was 2,502 (95% CI 1,856–3,374) per 100,000 person-years in
the first 6 months of treatment and 270 (206–356) thereafter. Fig 2 shows the decreasing risk
of death after the first 6 months of cART, in all calendar periods and country groups. The
probability of survival to 5 years after initiating cART was 97.6% (97.0%–98.1%) overall and
improved with calendar period from 96.2% (94.8%–97.2%) in 1997–2004 to 98.4% (97.2%–
99.1%) for 2008 onwards. Overall, it was 98.7% (98.0%–99.1%) in W&CE countries and 95.8%
(94.4%–96.8%) in EE&T countries. The mortality rate was highest in earlier calendar years,
peaking at 1,773 (95% CI 1,030–3,054) per 100,000 person-years in 2003 and decreasing to 360
in 2006, after which it was relatively stable at between 122 and 435 cases per 100,000 person-
years (Fig 3), with a similar trend for deaths both before and after 6 months of cART (S1 Fig).
Table 1. (Continued)
Characteristics Overall
(N = 3,526)
Died6 months after cART initiation
(N = 43)
Died >6 months after cART initiation
(N = 51)
n (%) or median [IQR]
BMI-for-age z-score (n = 1,872, 29, 27) −0.2 [−1.1–0.8] −2.8 [−3.8–−0.8] −1.5 [−2.7–−0.3]
See Methods for definition.
† Other ethnicity: 950 children reported as white, 23 Hispanic, 8 mixed, 1 indigenous.
cART, combination antiretroviral therapy; CD4%, CD4 lymphocyte percentage; NNRTI; nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
https://doi.org/10.1371/journal.pmed.1002491.t001
Fig 1. CD4% (left panel) and count (right panel) at initiation of cART, by age group and calendar period. cART,
combination antiretroviral therapy; CD4%, CD4 lymphocyte percentage.
https://doi.org/10.1371/journal.pmed.1002491.g001
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The peak in mortality rate in 2003 coincided with the introduction of cART in Thailand, and
Thailand accounted for over half of the deaths in the periods for both early and late deaths
(Table 1).
The median age at death was 9.5 (IQR 3.3–13.9) years; those who died within 6 months of
cART initiation were younger than those who died after 6 months (median age 6.5 versus 12.8,
p< 0.001). Among those who died after 6 months of cART, the median (IQR) viral load was
9,393 (400–107,654), CD4% was 6% (2%–24%), and CD4 count (among children aged5
years, n = 26) was 68 (9–304) cells/mm3. Twelve (24%) children with late deaths were not tak-
ing cART at the time of death, and a further 4 (8%) had a treatment interruption of>30 days
in the 6 months prior to death.
Overall, 58 (64%) deaths were due to HIV-related infections, predominantly bacterial infec-
tion and/or sepsis (Table 2), and these accounted for 76% (31/41 with cause available) of early
deaths and 55% (27/49) of late deaths (p = 0.043). Twenty-four deaths (27%) were from other
HIV-related causes (22% versus 31% early versus late, p = 0.355), 8 (9%) were not directly
Fig 2. Kaplan-Meier survival curve for time from cART initiation to death (A) by calendar period of cART initiation,
(B) by country group, and (C) by calendar period and country group. ART, antiretroviral therapy; cART,
combination antiretroviral therapy; EE&T, Eastern Europe and Thailand; W&CE, Western and Central Europe.
https://doi.org/10.1371/journal.pmed.1002491.g002
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related to HIV (2% versus 14%, p = 0.049), and 4 causes were unknown. Over the calendar
periods 2000–2004, 2005–2008, and 2009 onwards, the proportions of deaths caused by HIV-
related infections (19/30: 63%, 21/29: 72%, and 18/31: 58%, respectively) and other HIV-
related causes (10/30: 33%, 3/29: 10%, and 11/31: 35%, respectively) did not significantly
change (p = 0.504 and p = 0.053, respectively). Overall, 45 (50%) deaths were AIDS related
(59% of early deaths versus 43% later, p = 0.138), with no discernible trend by calendar year
period (8/30: 27%, 15/29: 52%, 11/31: 35%) or country group (EE&T: 30/59, 51%; W&CE: 15/
31, 48%; p = 0.824). Twenty-five (27%) children who died did not have an AIDS-defining ill-
ness at the time of their death; their most common cause of death was bacterial infection/
sepsis.
Of the 51 late deaths, 21 (41%) were in adolescents aged14 years. Median ages at HIV
diagnosis and cART initiation of these 21 children were 9.9 (IQR 8.5–11.3) and 10.8 (8.7–11.9)
years, respectively, and median duration of cART was 6.2 (4.5–7.6) years. Thirteen (62%) of
these deaths were due to an HIV-related infection, 6 to other HIV-related causes, and 2 were
unrelated to HIV.
Risk factors for death
In multivariable analysis, being in the first year of life, EE&T country group, AIDS diagnosis at
cART initiation, initiating cART on an NNRTI-based regimen (versus any other), severe
immune suppression for age, and low BMI-for-age z-score were associated with increased risk
of early death (Table 3). Sensitivity analysis replacing BMI-for-age z-score with weight-for-age
z-score resulted in similar estimates (S1 Table).
Rates and risk factors for death after 6 months of cART are shown in Table 4. In multivari-
able analysis, no baseline characteristics were strongly associated with higher risk of late death.
Time-updated characteristics associated with higher risk of death were severe immune sup-
pression for age, current viral load >400 c/mL, and low current BMI-for-age z-score. There
was a nonsignificantly elevated risk of late death in EE&T (p = 0.073). After adjustment for
other factors, year of cART initiation was no longer associated with early or late death.
Fig 3. Mortality rates (95% CI) by calendar year of follow-up, 2000–2013.
https://doi.org/10.1371/journal.pmed.1002491.g003
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In the sensitivity analysis, the model with weight-for-age z-score was broadly similar to the
BMI model (S2 Table), but the effect of weight-for-age at ART start was attenuated (>0
adjusted hazard ratio [aHR] 0.57 [0.11–2.88], <−3 aHR 1.07 [0.32–3.63], unknown aHR 1.21
[0.46–3.15] versus −3–0, p = 0.875).
AIDS-defining events
Among those without an AIDS diagnosis by the start of cART (n = 2,863), 278 AIDS-defining
events were reported in 237 children: 113 (41%) were from Thailand, 75 (27%) in the UK or
Table 2. Causes of death for children who died, overall, and by timing of death.
Category Cause Total (N = 94) Time since cART initiation
6 months (N = 43) >6 months (N = 51)
n (%)
HIV-related infections Bacterial infection and/or sepsis 26 15 11
(Bacterial pneumonia/pneumosepsis) (13) (9) (4)
Cryptococcosis 6 1 5
PJP 6 4 2
Tuberculosis 3 2 1
Nontuberculous mycobacteria 4 1 3
CMV 3 2 1
PJP + CMV 3 2 1
Cerebral toxoplasmosis 2 2 0
Unspecified 1 0 1
Other1 4 2 2
Total HIV related 58 (64%) 31 (76%) 27 (55%)
Other HIV related Wasting syndrome 8 3 5
Heart failure/cardiomyopathy 6 4 2
Malignant neoplasm2 4 1 3
Haemorrhage3 3 0 3
Encephalopathy 1 1 0
Lactic acidosis 1 0 1
Myelodysplasia 1 0 1
Total other HIV related 24 (27%) 9 (22%) 15 (31%)
Not directly HIV related Haemorrhage4 2 1 1
Suicide 2 0 2
Accident 1 0 1
Atrioventricular block 1 0 1
Congenital malformation 1 0 1
Diabetes mellitus 1 0 1
Total not directly HIV related 8 (9%) 1 (2%) 7 (14%)
Unknown Total unknown 4 2 2
Subset of previous category.
1 1 cysticercosis of the central nervous system, 1 geotrichosis, 1 fungal pneumonia, 1 progressive multifocal leukoencephalopathy.
2 1 Kaposi sarcoma, 1 non-Hodgkin’s lymphoma, 2 unspecified.
3 2 cerebral haemorrhages, categorised as HIV-related as they occurred with other HIV-related conditions, such as chronic thrombocytopenia, that could lead to
haemorrhage.
4 1 cerebral, 1 haematemesis. No other HIV-related conditions that could have explained haemorrhage were reported.
cART, combination antiretroviral therapy; CMV, cytomegalovirus; PJP, Pneumocystis jirovecii pneumonia.
https://doi.org/10.1371/journal.pmed.1002491.t002
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Ireland, 48 (17%) in Russia or Ukraine, and 42 (15%) in the rest of W&CE. The overall rate of
first AIDS-defining event was 1,549 (95% CI 1,364–1,760) per 100,000 person-years and was
higher in the first 6 months of cART (7,305 [6,005–8,887]) compared to later (984 [832–1,163],
p< 0.001). The most commonly reported AIDS events were encephalopathy (38 events in 38
children, 14%), tuberculosis (TB)(34 events in 32 children, 12%), and wasting syndrome (31
events in 30 children, 11%) (Table 5).
Among the 663 children with an AIDS diagnosis prior to cART initiation, there were a fur-
ther 80 AIDS-defining events after initiation of cART in 66 (10%) children. The most common
Table 3. Rates and baseline risk factors for death within 6 months of cART initiation.
Baseline characteristics at initiation of cART N deaths Rate per 100,000 PY (95% CI) Univariable Multivariable
HR 95% CI p HR 95% CI p
Sex Male 18 2,208 (1,391–3,504) 0.80 0.44–1.47 0.469 0.86 0.45–1.64 0.656
Female 25 2,769 (1,871–4,098) 1.00 - 1.00 -
Age (per year increase) <2 years 16 3,143 (1,925–5,130) 0.43 0.25–0.73 0.024 0.31 0.13–0.73 0.048
2–<8 years 12 1,852 (1,052–3,261) 1.27 1.04–1.54 1.23 0.97–1.56
8 years 15 2,674 (1,612–4,435) 0.93 0.76–1.13 0.94 0.72–1.23
Year of birth (per year increase) <2003 31 2,777 (1,953–3,949) 0.93 0.87–1.00 0.012 -
2003–<2007 4 1,208 (453–3,219) 0.87 0.64–1.19
2007 8 2,954 (1,477–5,906) 1.55 1.12–2.14
Place of birth Within country 27 2,435 (1,670–3,551) 1.00 - <0.001 -
Abroad 8 1,507 (754–3,013) 0.62 0.28–1.37
Unknown 8 10,172 (5,087–20,340) 4.19 1.90–9.25
Ethnicity Black African 10 1,732 (932–3,220) 0.24 0.12–0.50 <0.001 -
Asian 25 7,215 (4,875–10,677) 1.00 -
Other 6 1,258 (565–2,800) 0.17 0.07–0.43
Unknown 2 630 (158–2,520) 0.09 0.02–0.37
Country group W&CE 14 1,304 (772–2,201) 0.29 0.15–0.55 <0.001 0.39 0.17–0.89 0.025
EE&T 29 4,501 (3,128–6,477) 1.00 - 1.00 -
AIDS diagnosis No AIDS 17 1,214 (755–1,953) 1.00 - <0.001 1.00 - <0.001
AIDS 26 8,183 (5,571–12,018) 6.73 3.65–12.43 3.91 2.00–7.64
Year of cART initiation (per year increase) - - 0.65 0.43–0.96 0.032 0.85 0.54–1.33 0.469
Initial regimen NNRTI-based 36 3,312 (2,389–4,592) 1.00 - 0.008 1.00 - 0.057
PI-based/other 7 1,109 (529–2,326) 0.33 0.15–0.75 0.43 0.18–1.03
Immune suppression for age Not severe 6 1,002 (450–2,230) 0.20 0.08–0.47 <0.001 0.37 0.15–0.91 0.004
Severe 36 5,006 (3,611–6,940) 1.00 - 1.00 -
Unknown 1 250 (35–1,774) 0.05 0.01–0.37 0.08 0.01–0.55
Viral load (c/mL) 100,000 12 2,083 (1,183–3,667) 0.63 0.31–1.27 0.260 0.89 0.41–1.92 0.955
>100,000 21 3,349 (2,183–5,136) 1.00 - 1.00 -
Unknown 10 1,942 (1,045–3,610) 0.59 0.28–1.24 0.95 0.41–2.21
BMI-for-age z-score >0 5 1,193 (497–2,866) 0.44 0.15–1.24 <0.001 1.02 0.32–3.22 0.006
−3–0 12 2,726 (1,548–4,800) 1.00 - 1.00 -
<−3 12 26,209 (14,884–46,150) 9.47 4.23–21.19 4.64 1.90–11.34
Unknown 14 1,722 (1,020–2907) 0.64 0.29–1.38 1.30 0.57–3.44
Notes: The following variables were excluded from the multivariable model due to correlation: year of birth (with age and, also, year of cART initiation); place of birth
(with country group); ethnicity (with country group).
cART, combination antiretroviral therapy; EE&T, Eastern Europe and Thailand; HR, hazard ratio; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease
inhibitor; PY, person years; W&CE, Western and Central Europe.
https://doi.org/10.1371/journal.pmed.1002491.t003
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Table 4. Rates and risk factors (baseline and time updated) for death after 6 months of cART.
Baseline characteristics at initiation of cART N deaths Rate per 100,000 PY (95% CI) Univariable Multivariable
HR 95% CI p HR 95% CI p
Sex Male 21 232 (151–356) 0.74 0.42–1.29 0.290 0.91 0.51–1.59 0.731
Female 30 306 (214–437) 1.00 - 1.00 -
Age (per year increase) <2 years 9 155 (81–298) 0.80 0.47, 1.38 <0.001 0.67 0.34–1.31 0.309
2 years 42 322 (238–435) 1.18 1.09–1.27 1.08 0.97–1.20
Year of birth (per year increase) <1995 20 567 (366–878) 0.98 0.82–1.17 <0.001 -
1995–<2000 19 270 (172–423) 0.72 0.58–0.89
2000 12 145 (82–255) 1.06 0.88–1.27
Place of birth Within country 37 302 (219–417) 1.00 - 0.066 -
Abroad 9 159 (83–305) 0.50 0.24–1.04
Unknown 5 531 (221–1277) 1.71 0.67–4.38
Ethnicity Black African 35 7,447 (5,347–10,372) 0.56 0.35–0.90 0.012 -
Asian 35 13,250 (9,514–18,455) 1.00 -
Other 25 6,573 (4,441–9,727) 0.50 0.30–0.83
Unknown 15 5,899 (3,557–9,786) 0.45 0.24–0.82
Country group W&CE 18 142 (90–226) 0.25 0.13, 0.45 <0.001 0.48 0.22–1.07 0.073
EE&T 33 531 (377–747) 1.00 - 1.00 -
AIDS diagnosis No AIDS 37 245 (178–338) 1.00 - 0.218 1.00 - 0.169
AIDS 14 372 (221–629) 1.48 0.79–2.75 1.53 0.84–2.80
Year of cART initiation (per year increase) - - 0.62 0.39–0.99 0.044 0.62 0.35–1.91 0.091
Initial regimen NNRTI-based 43 328 (243–442) 1.00 - 0.018 1.00 - 0.637
PI-based/other 8 139 (70–279) 0.40 0.19–0.86 0.82 0.35–1.91
Immune suppression for age Not severe 5 85 (35–204) 0.26 0.10–0.68 0.019 0.77 0.24–2.49 0.875
Severe 30 357 (250–511) 1.00 - 1.00 -
Unknown 16 349 (214–570) 1.00 0.54–1.84 1.02 0.42–2.45
VL (c/mL) 100,000 13 214 (124–369) 0.94 0.45–1.96 0.247 0.72 0.36–1.44 0.615
>100,000 17 241 (150–387) 1.00 - 1.00 -
Unknown 21 366 (239–562) 1.57 0.82–2.99 0.80 0.37–1.77
BMI-for-age z-score >0 2 42 (10–166) 0.09 0.02–0.38 0.007 0.18 0.04–0.76 0.078
−3–0 22 440 (289–668) 1.00 - 1.00 -
<−3 3 556 (179–1,723) 1.20 0.35–4.10 0.46 0.14–1.51
Unknown 24 282 (189–421) 0.63 0.35–1.12 0.71 0.27–1.83
Time updated characteristics
Age (per year increase) <5 years 7 186 (89–390) 0.65 0.45–0.95 <0.001 -
5 years 44 292 (217–292) 1.22 1.13–1.32
Immune suppression for age Not severe 9 67 (35–128) 0.02 0.01–0.05 <0.001 0.07 0.02–0.17 <0.001
Severe 30 2,617 (1,830–3,743) 1.00 - 1.00 -
Unknown 12 285 (162–502) 0.10 0.05–0.20 0.19 0.05–0.73
VL (c/mL) 400 12 102 (58–179) 0.10 0.05–0.21 <0.001 0.32 0.13–0.78 0.028
>400 25 958 (647–1,418) 1.00 - 1.00 -
Unknown 14 315 (187–532) 0.33 0.17–0.65 0.63 0.18–2.27
% time since cART initiation with VL400 c/mL <80% 30 477 (334–682) 1.00 - <0.001 -
80% 7 86 (41–181) 0.18 0.08–0.41
Unknown 14 315 (187–532) 0.67 0.35–1.28
BMI-for-age z-score >0 8 130 (65–260) 0.55 0.23–1.30 <0.001 1.14 0.43–2.97 <0.001
−3–0 14 230 (136–388) 1.00 - 1.00 -
<−3 12 9,006 (5,115–15,859) 42.27 19.30–92.57 17.37 6.31–47.82
Unknown 17 262 (163–421) 1.12 0.54–2.32 1.61 0.59–4.44
Notes: The following variables were excluded from the multivariable model due to correlation: year of birth (with age and also year of cART initiation); place of birth
(with country group); ethnicity (with country group); time-updated age (with age and also year of cART initiation); proportion of time with VL 400 c/mL (with time-
updated VL).
cART, combination antiretroviral therapy; EE&T, Eastern Europe and Thailand; HR, hazard ratio; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease
inhibitor PY, person years; VL, viral load; W&CE, Western and Central Europe.
https://doi.org/10.1371/journal.pmed.1002491.t004
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events were encephalopathy (21 events in 21 children, 26%), multiple/recurrent bacterial infec-
tions (11 events in 10 children, 14%), and TB (11 events in 8 children, 14%); 61 events had a
missing cause.
Risk factors for first AIDS-defining events after cART initiation in those
with no previous AIDS diagnosis
In multivariable analysis, factors associated with increased risk of the first AIDS-defining
event within 6 months of cART initiation were severe immunosuppression and lower BMI-
for-age z-score (<−3 versus 0–−3) at cART initiation (S3 Table). Factors associated with
increased risk after 6 months of cART were earlier year of cART initiation, initiating cART on
an NNRTI-based regimen (versus any other), higher viral load at cART initiation, severe cur-
rent immune suppression for age for those in EE&T, current viral load>400 c/mL, and lower
current BMI-for-age z-score (S4 Table).
Discussion
Our study included more than 3,500 children and young adults with HIV infection followed
across 16 Western, Central, and Eastern European countries and Thailand. Median age at
Table 5. Rates of AIDS-defining events among children with no previous AIDS diagnosis at initiation of cART,
N = 2,863.
Event Number of children with an
event (number of events)
Rate of first event per
100,000 PY (95% CI)
TOTAL 237 (278) 1,549 (1,364–1,760)
Encephalopathy attributed to HIV 38 (38) 233 (170–321)
Mycobacterium tuberculosis of any site, pulmonary (6
years), disseminated, or extrapulmonary
32 (34) 195 (138–276)
Wasting syndrome attributed to HIV 30 (31) 184 (128–263)
Bacterial infections, multiple or recurrent (<6 years) 27 (32) 166 (114–241)
PJP 23 (23) 140 (93–211)
Cytomegalovirus disease (other than liver, spleen, or
nodes), onset at age >1 month, or retinitis (with loss of
vision)
11 (13) 67 (37–121)
Mycobacterium, other species, or unidentified species,
disseminated or extrapulmonary
11 (11) 67 (37–121)
Cryptococcosis, extrapulmonary 8 (11) 29 (24–97)
Candidiasis of bronchi, trachea, esophagus, or lungs 6 (6) 36 (16–81)
Cryptosporidiosis, chronic intestinal (>1 month duration) 3 (3) 18 (6–56)
M. avium complex or M. kansasii, disseminated or
extrapulmonary
3 (3) 18 (6–56)
Progressive multifocal leukoencephalopathy 3 (3) 18 (6–56)
Herpes simplex virus: chronic ulcers (>1 month duration)
or bronchitis, pneumonitis, or esophagitis (onset at age >1
month)
2 (2) 12 (3–49)
Kaposi sarcoma 2 (3) 12 (3–48)
Lymphoma, immunoblastic (or equivalent term) 2 (2) 12 (3–48)
Pneumonia, recurrent (6 years) 1 (1) 6 (1–43)
Salmonella spp. septicemia, recurrent 1 (1) 6 (1–43)
Undefined event 61 (61) 377 (294–485)
cART, combination antiretroviral therapy; PJP, Pneumocystis jirovecii pneumonia.
https://doi.org/10.1371/journal.pmed.1002491.t005
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cART initiation was 5 years and median follow-up 5 years, with a quarter of participants being
followed for9 years. The median year of birth was 2000, with a quarter being born before
1997; thus, many children were born before the introduction of cART, and outcomes in older
children who survived reflect the first cohort of patients with perinatal HIV progressing to
adult life [13]. Nearly half of all deaths (46%) and 42% of first AIDS-defining events were
within 6 months of cART start in our study. We found that multivariable predictors of early
death were very young age, residence in Eastern European countries and Thailand, AIDS diag-
nosis at cART initiation, initiating cART on an NNRTI-based regimen, severe immune sup-
pression for age, and low BMI-for-age z-score at cART initiation. Time-updated (current)
severe immune suppression for age and low BMI-for-age z-score were also associated with late
death, as was current viral load >400 c/mL.
Our results confirm that mortality rates in children starting treatment across the European
region and Thailand fell markedly since the introduction of cART in 1996 but also suggest that
they have remained stable since 2006, at 122 and 435 deaths per 100,000 person-years, respec-
tively. Our 5-year survival probability after initiating cART was 97.6% overall, and was higher
in W&CE countries than EE&T. These findings are consistent with results from other studies.
For example, a study of HIV-infected youth in the US reported mortality rates of 660 per
100,000 person years (PY) for the period 2008–2014 and a 5-year survival probability of 97.6%
[16], and another US study reported survival probabilities of 76% at 6 years for those born in
1991–1996 and exposed to mono or dual therapy, and 91% at 6 years for those born in 1997–
2004 and exposed to cART [3].
Interestingly, our results suggest that mortality rates (and also incidence of first AIDS
events) in children initiating cART in the European region and Thailand have not declined
since 2006. It is encouraging that the proportion of children presenting late decreased over
time, but from 2011 onwards, 1 in 7 children aged<5 years and 1 in 5 children aged5 years
at cART initiation still presented with CD4% < 15 or CD4 count <200 cells/mm3, despite the
CD4 threshold for initiating treatment increasing over time [17]. This highlights the ongoing
importance of identifying and testing children most at risk of HIV. Enhanced prophylaxis
against infections has been shown to reduce the risk of early death in adults and children with
advanced disease in low-income countries [18] and may be relevant in our high-income set-
ting, especially as a third of patients in our study were born abroad, many in sub-Saharan
Africa. Further work is needed to ascertain possible contributing factors, such as late HIV
diagnosis, suboptimal immune reconstitution despite cART, late access to cART, nonadher-
ence, ART toxicity, and socioeconomic factors. Our results suggest that mortality rates in
HIV-infected children initiating cART in the European region are 3–12 times higher than in
the general population, as the mortality rate for 0–14-year-olds in 27 countries in the European
Union (EU) in 2013 was 35 per 100,000 person-years [19]. Similarly, higher rates of mortality
have been found in perinatally HIV-infected older youth compared to the general population
in the US [20].
Almost half of all deaths (46%) occurred in the first 6 months of cART, with the majority
already having an AIDS diagnosis by the time of cART initiation. Indeed, AIDS may have
been an indication for initiating treatment at the time, and with guidelines now recommend-
ing universal treatment for HIV [21], it is unlikely that we would observe so many deaths now,
with a higher proportion of children being diagnosed earlier (when asymptomatic), through
screening. The Therapeutic Research, Education and AIDS Training (TREAT) Asia Pediatric
HIV Observational Database (TApHOD) cohort of children in Asia-Pacific found similar
results [22], and very young age has been found to predict mortality in other studies [23–26].
In our study, three-quarters of early deaths were due to HIV-related infections, with bacterial/
sepsis-related causes being the most common, whilst 22% were due to other HIV-related
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causes, and only 1 death had a cause not directly related to HIV. Some of these early deaths
may have been associated with immune reconstitution inflammatory syndrome [27,28]. The
causes of early death contrast with the deaths after 6 months, of which 14% were not directly
related to HIV. The trend in causes of death (i.e., HIV-related infections, other HIV-related
causes, and not HIV related) did not change over calendar periods, although we had limited
power for this. Similarly, we did not detect a decline over the calendar period in the proportion
of deaths attributed to AIDS, in contrast to other studies [2,3]. One study of adults with HIV
found different trends in the proportion of deaths due to AIDS by region across Europe and
Argentina [29], with higher risk of mortality from AIDS-related causes in Eastern Europe and
higher non-AIDS mortality in northern Europe.
The strongest predictors of mortality in our analysis were having an AIDS diagnosis at
cART initiation, current severe immune suppression for age, and being underweight. These
are known risk factors that have been consistently reported in many earlier HIV cohorts
[3,20,22]. As expected, children in W&CE countries had a lower risk of death within the first 6
months of cART initiation, perhaps due to better access to medical care, a higher standard of
clinical care, higher nutritional status, and better tolerated combinations of cART. One key
component of clinical care is vaccination against infectious diseases among children with HIV,
and this remains an area in which improvements can be made [30]. Of concern, our findings
indicate a raised mortality risk in the first year of life, independent of AIDS diagnosis and
immune suppression for age, similar to other study findings [31,32]. This suggests the need for
continued vigilance in this group.
Among those who did not have AIDS prior to initiating treatment, 6% of children had a
subsequent AIDS-defining event, with the most commonly reported events being encephalop-
athy, TB, and wasting syndrome. Predictors of first AIDS-defining event were similar to those
found for death.
Our study has a number of limitations. We analysed observational data from several
cohorts across the European region and Thailand, but events were distributed over a long time
period and we lacked statistical power to investigate trends over calendar time of patterns and
causes of death in some analyses. Data were not collected in a standardised way across cohorts,
but we took time to verify causes of death with reporting clinicians, and each cohort had their
own system for data validation and querying. We were unable to analyse data on serious
adverse events and CDC disease stage B events, as these were incompletely collected across
cohorts. For a small number of children with an AIDS event, information on the type of AIDS
event was not available. Around half (52%) of patients came from the UK/Ireland or Thailand,
but these countries accounted for 81% of the deaths observed. Conversely, 6 (38%) of the 16
countries that observed no deaths at all (Germany, Greece, the Netherlands, Portugal, Roma-
nia, and Sweden) only accounted for 9% of patients.
In conclusion, in our study of more than 3,500 children across the European region and
Thailand, mortality rates fell after the introduction of cART in 1997 but have remained stable
since 2006, and the prevalence of low CD4 at initiation of cART decreased over the period.
Five-year survival probability after initiating cART across the whole period studied was 97.6%.
Almost half (46%) of the 94 deaths observed were in the first 6 months of cART, suggesting
that close clinical follow-up is recommended over the first 6 months after cART initiation,
with enhanced prophylaxis against infections in those presenting with advanced disease. The
indication of raised early mortality risk in infants and those in EE&T raises concern and war-
rants vigilance. It highlights the need to direct additional clinical resources to the care of these
groups, as well as further prospective studies evaluating morbidity and mortality in older
adolescents.
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